Literature DB >> 1929228

Serum interleukin-2 concentrations in Guillain-Barré syndrome and chronic idiopathic demyelinating polyradiculoneuropathy: comparison with other neurological diseases of presumed immunopathogenesis.

H P Hartung1, K Reiners, B Schmidt, G Stoll, K V Toyka.   

Abstract

Serum concentrations of the cytokine interleukin-2 (IL-2) were quantitated by enzyme-linked immunosorbent assay in 42 patients with Guillain-Barré syndrome, 15 patients with chronic idiopathic demyelinating polyradiculoneuropathy, 37 patients with other neuropathies, 54 patients with other noninflammatory, nondemyelinating neurological disorders, and 26 healthy control subjects. We found markedly increased serum levels of IL-2 in patients with Guillain-Barré syndrome and to a much lesser extent, in patients with chronic idiopathic demyelinating polyradiculoneuropathy. Increased serum concentrations of IL-2 in patients with Guillain-Barré syndrome returned to normal in parallel with recovery from the disease. These findings suggest ongoing T-cell proliferation in patients with Guillain-Barré syndrome and some patients with chronic idiopathic demyelinating polyradiculoneuropathy. IL-2 levels were also raised in patients with active multiple sclerosis, myasthenia gravis, and herpes simplex encephalitis, and some patients with polymyositis, invoking T cells in the pathogenesis of these diseases.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1929228     DOI: 10.1002/ana.410300110

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  27 in total

1.  Potential role of transforming growth factor-beta 1 in terminating the immune response in patients with Guillain-Barré syndrome.

Authors:  E Sindern; K Schweppe; L M Ossege; J P Malin
Journal:  J Neurol       Date:  1996-03       Impact factor: 4.849

Review 2.  Advances in the diagnosis, pathogenesis and treatment of CIDP.

Authors:  Marinos C Dalakas
Journal:  Nat Rev Neurol       Date:  2011-08-16       Impact factor: 42.937

Review 3.  Autoimmune responses in peripheral nerve.

Authors:  H P Hartung; H Willison; S Jung; M Pette; K V Toyka; G Giegerich
Journal:  Springer Semin Immunopathol       Date:  1996

4.  Circulating transforming growth factor beta 1 (TGF-beta1) in Guillain-Barré syndrome: decreased concentrations in the early course and increase with motor function.

Authors:  A Créange; L Bélec; B Clair; J D Degos; J C Raphaël; R K Gherardi
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-02       Impact factor: 10.154

Review 5.  Immune-mediated neuropathies.

Authors:  Bernd C Kieseier; Emily K Mathey; Claudia Sommer; Hans-Peter Hartung
Journal:  Nat Rev Dis Primers       Date:  2018-10-11       Impact factor: 52.329

6.  T cell reactivity to P0, P2, PMP-22, and myelin basic protein in patients with Guillain-Barre syndrome and chronic inflammatory demyelinating polyradiculoneuropathy.

Authors:  P A Csurhes; A-A Sullivan; K Green; M P Pender; P A McCombe
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-10       Impact factor: 10.154

Review 7.  Multiple sclerosis: a unique immunopathological syndrome of the central nervous system.

Authors:  S F Hunter; M Rodriguez
Journal:  Springer Semin Immunopathol       Date:  1995

8.  Soluble interleukin-2 receptor levels in serum of patients with demyelinating polyneuropathy associated with monoclonal gammopathy.

Authors:  M Vrethem; T Skogh; J Ernerudh; B Ekstedt; O Andersen; J Lycke
Journal:  J Neurol Neurosurg Psychiatry       Date:  1993-06       Impact factor: 10.154

9.  Tumour necrosis factor-alpha and other cytokines in Guillain-Barré syndrome.

Authors:  A R Exley; N Smith; J B Winer
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-09       Impact factor: 10.154

10.  Local anaesthetic-like effect of interleukin-2 on muscular Na+ channels: no evidence for involvement of the IL-2 receptor.

Authors:  A Kaspar; H Brinkmeier; R Rüdel
Journal:  Pflugers Arch       Date:  1994-01       Impact factor: 3.657

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.